Vol. 21, Issue 1, 2021November 18, 2021 CDT
ccby-4.0
The Future of Stem Cell Therapy Regulation Under the FDA’s Comprehensive Regenerative Medicine Policy Framework Through a Public Health Lens
The Future of Stem Cell Therapy Regulation Under the FDA’s Comprehensive Regenerative Medicine Policy Framework Through a Public Health Lens
stem cell researchregenerative medicineComprehensive Regenerative Medicine Policy Frameworkpublic healthstem cell therapyright-to-try movementFDA
Articles in Vol. 21, Issue 1, 2021
Vol. 21, Issue 1, 2021
- 8th Annual Symposium: Redefining & Regulating Health DataLeah Fowler
- Second Thoughts on FDA’S COVID-Era Mental Health App PolicyMichael Mattioli
- Location as HealthAnya E. R. Prince
- Health-Based Proxy Discrimination, Artificial Intelligence, and Big DataDaniel Schwarcz
- AI's Legitimate Interest: Towards a Public Benefit Privacy ModelCharlotte Tschider
- The Future of Stem Cell Therapy Regulation Under the FDA’s Comprehensive Regenerative Medicine Policy Framework Through a Public Health LensLeah Nadel
- Pandemic Policy: Protecting the Public Health of the United States by Federally Criminalizing the Wrongful Transmission of Foreign Infectious DiseaseLizzie Hardage
Leah Nadel, The Future of Stem Cell Therapy Regulation Under the FDA’s Comprehensive Regenerative Medicine Policy Framework Through a Public Health Lens, 21 HOUS. J. HEALTH L. & POL’Y 223 (2021).